美国结节型与浅表扩散型黑色素瘤患者的五年生存率比较
基于SEER数据的横断面分析比较结节型黑色素瘤(NM)与浅表扩散型黑色素瘤(SSM)在相同Breslow厚度和TNM分期下的5年相对生存率。2004-2009年诊断患者中NM的5年相对生存率低于SSM(53.7% vs 87.3%;Z分数,-41.35;P < .001),2010-2015年诊断患者中同样较低(61.5% vs 89.7%;Z分数,-2.7078;P < .01)。亚组分析显示T1b期NM生存更差,排除淋巴结或远处转移患者后差异仍显著。结论认为NM的5年相对生存率劣于SSM,尤其在T1b、T2a和T2b期,制定治疗建议时应考虑黑色素瘤亚型。
要点
- 相同Breslow厚度和TNM分期下,NM的5年相对生存率低于SSM。
- T1b期NM生存劣势显著,排除转移患者后差异仍存在。
- 制定黑色素瘤治疗建议时应考虑组织学亚型。
核心结论
- NM的5年相对生存率劣于SSM,尤其在T1b、T2a和T2b期黑色素瘤中。
研究设计与样本
- 基于SEER数据的群体横断面分析,使用卡方检验比较比例,Kaplan-Meier法和Z分数比较5年相对生存率。
主要发现
- 2004-2009年诊断患者中,NM的5年相对生存率为53.7%,SSM为87.3%(Z分数,-41.35;P < .001)。
- 2010-2015年诊断患者中,NM的5年相对生存率为61.5%,SSM为89.7%(Z分数,-2.7078;P < .01)。
- 亚组分析显示T1b期NM生存更差,排除淋巴结或远处转移患者后生存差异仍显著。
关键数值与推荐
- 5年相对生存率比较:NM vs SSM在2004-2009年为53.7% vs 87.3%(P < .001),2010-2015年为61.5% vs 89.7%(P < .01)。
临床怎么用
- 制定黑色素瘤治疗建议时应考虑组织学亚型,NM患者可能需要更积极的评估和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although superficial spreading melanomas (SSM) are diagnosed as thinner lesions, nodular melanomas (NM) have a more rapid growth rate and are biologically more aggressive compared with other histologic subtypes. OBJECTIVE: To determine the difference in 5-year relative survival in patients with NM and SSM at the same Breslow depth and TNM stage. METHODS: A population-based cross-sectional analysis compared the 5-year relative survival of patients with NM and SSM using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER)∗Stat software (version 8.2.1-8.3.5). Chi-square tests compared the proportions, and Kaplan-Meier method with Z-score compared 5-year relative survival. RESULTS: For patients receiving a diagnosis between 2004 and 2009, 5-year relative survival was lower in NM compared with SSM (53.7% vs 87.3%; Z score, -41.35; P < .001). Similarly, for patients receiving a diagnosis between 2010 and 2015, 5-year relative survival was lower in NM compared with SSM (61.5% vs 89.7%; Z score, -2.7078; P < .01). Subgroup analyses showed inferior survival in NM in T1b, and survival differences remained significant after excluding patients with nodal or distant metastases. CONCLUSIONS: Five-year relative survival is worse in NM compared with SSM especially in T1b, T2a, and T2b melanomas. Melanoma subtype should be taken into consideration when making treatment recommendations.
引用
- Allais BS, Beatson M, Wang H, et al. Five-year survival in patients with nodular and superficial spreading melanomas in the US population. J Am Acad Dermatol. 2020. PMID: 33253834. doi:10.1016/j.jaad.2020.11.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。